ZOPHREN 16 mg, suppository 2 suppositories
Active ingredients: Ondansetron
Commercialized according to BDPMDispensing in France: Prescription only
Suppository2 suppositoriesrectale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ZOPHREN 16 mg, suppositoire
- Pharmaceutical form
- suppositoire
- Route of administration
- rectale
- Presentation description
- plaquette(s) polyéthylène aluminium polypropylène de 2 suppositoire(s)
- Marketing authorisation holder
- NOVARTIS PHARMA
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 20 Dec 2022
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
66794860CIP73438808CIP133400934388088Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ONDANSÉTRONsuppositoire | 16 mg · un suppositoire | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.